Clinical study on valsartan and simvastatin in early diabetic nephropathy
- VernacularTitle:缬沙坦联合辛伐他汀治疗早期糖尿病肾病临床观察
- Author:
Hongdan LIU
;
Jianhua LI
;
Jing FAN
- Publication Type:Journal Article
- Keywords:
Diabetic nephropathies;
Albuminufia;
Angiotensin Ⅱ Type 1 receptor blockers;
valsartan;
simvas-tafin
- From:
Chinese Journal of Primary Medicine and Pharmacy
2008;15(10):1597-1598
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the effects and the functions of valsartan and simvastatin in early diabetic nephropathy. Methods A total of 80 patients with early diabetic nephropahy were randomly divided into two groups.The patients in control group(n=40)received valsartan at a dose of 80rag/day ,while in treated group(n=40)on the base of the same treatment as control group, added simvastatin 20 mg/everyrfight. To compare the differences of lipids,urine albumin excretion rate(UAER) and C-reactive protein(CRP) before or after treatments through 12 weeks. Re-sults The UAER of two groups decreased obviously after therapy,especially the treated group(P<0.01) ;the lipids and CRP also decreased evidently in the treated group (P<0.05). Conclusion The lipids, UAER, CRP of patients in early diabetic nephropathy could be down-regulated,with combined medication of the simvastatin and valsartan, and the injury of renal alleviated.
